

Drugs Which May Be Used Based on Licensure Designation

Approved Drugs

- a.) *Administration and prescription of pharmaceutical agents for therapeutic purposes.* Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes.
- b.) *Administration and prescription of pharmaceutical agents to treat glaucoma.* Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma.
- c.) *Administration and prescription of pharmaceutical agents for analgesic purposes.* Optometrists who hold a DEA registration are certified to prescribe pharmaceutical agents listed in section 8 under oral analgesics. A licensee who holds or plans to obtain a DEA registration is reminded to review and comply with PDMP standards and to obtain 2 hours of continuing education regarding opioid prescribing and management in addition to the required number of required hours for therapeutics.
- d.) *DEA registration reminder.* Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with [PDMP](#) standards.
- e.) *Allowable pharmaceutical products.* Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug:

(1) Topical Anesthetics

- (i) benoxinate
- (ii) lidocaine
- (iii) proparacaine
- (iv) tetracaine

(2) Topical Ocular Lubricants

- (i) Topical Irrigation
 - (A) lactated ringers

(3) Topical Ophthalmic Dyes and Stains

- (i) fluorescein
- (ii) fluorexon
- (iii) lissamine green
- (iv) rose bengal

(4) Topical Hyperosmotic Agents

(5) Autonomic Drugs – Topical Only

(i) Adrenergic Agonists

- (A) antazoline
- (B) hydroxyamphetamine hydrobromide
- (C) naphazoline
- (D) oxymetazoline
- (E) phenylephrine hydrochloride
- (F) tetrahydrozoline

(ii) Adrenergic Antagonists – Diagnostic Use Only

- (A) dapiprazole
- (B) thymoxamine

(iii) Cholinergic Agonists

- (A) DFP (diisopropylfluorophosphate)
- (B) echothiopate
- (C) physostigmine
- (D) pilocarpine nitrate and pilocarpine hydrochloride – diagnostic use only
- (E) varenicline

(iv) Cholinergic Antagonists

- (A) atropine sulfate
- (B) cyclopentolate hydrochloride
- (C) homatropine hydrobromide
- (D) scopolamine hydrobromide
- (E) tropicamide

(6) Nonsteroidal Anti-inflammatory Drugs – Topical Only

- (i) bromfenac
- (ii) diclofenac
- (iii) flurbiprofen
- (iv) ketorolac
- (v) nepafenac
- (vi) suprofen

(7) Antimicrobial Agents

(i) Antibacterial – Oral

(A) Cell Wall Inhibitors

- (I) cephalosporins
 - (-1-) First generation – cephalexin and cefadroxil
 - (-2-) Second generation – cefaclor and cefuroxime
- (II) penicillins – including in combination with clavulanic acid

(B) Protein Synthesis Inhibitors

- (I) azithromycin
- (II) doxycycline
- (III) erythromycin
- (IV) minocycline
- (V) tetracycline
- (VI) Clindamycin hydrochloride capsule

(C) DNA Synthesis Inhibitors

- (I) Ciprofloxacin hydrochloride tablet
- (II) Levofloxacin hydrochloride tablet
- (III) Moxifloxacin hydrochloride tablet

(D) Intermediary Metabolism Inhibitors

- (I) trimethoprim (specifically Bactrim and Bactrim DS)
- (II) sulfamethoxazole (specifically Bactrim and Bactrim DS)

(ii) Antibacterial – Topical Use Only

(A) Cell Membrane Permeability

- (I) gramicidin
- (II) polymyxin B

(B) Cell Wall Inhibitors

- (I) bacitracin
- (II) cephalosporins
- (III) penicillins
- (IV) povidone-iodine (Betadine)
- (V) vancomycin

(C) DNA Synthesis Inhibitors

- (I) besifloxacin
- (II) ciprofloxacin
- (III) gatifloxacin
- (IV) levofloxacin
- (V) moxifloxacin
- (VI) norfloxacin
- (VII) ofloxacin

(D) Intermediary Metabolism Inhibitors

- (I) sodium sulfacetamide and sulfisoxazole
- (II) trimethoprim

(E) Protein Synthesis Inhibitors

- (I) aminoglycosides
- (II) azithromycin
- (III) chloramphenicol
- (IV) erythromycin
- (V) tetracycline

(iii) Antifungal and Antiparasitic – Topical Only

- (A) amphotericin B, nystatin, natamycin
- (B) miconazole, ketoconazole, clotrimazole
- (C) neomycin and polymyxin B
- (D) paromomycin
- (E) thiabendazole

(iv) Antivirals – Oral

- (A) acyclovir
- (B) famciclovir
- (C) valacyclovir

(v) Antivirals – Topical Only

- (A) ganciclovir
- (B) idoxuridine
- (C) trifluridine
- (D) vidarabine
- (E) acyclovir

(8) Analgesic Drugs – Oral

(i) Analgesic Drugs – Oral

- (A) codeine in combination with acetaminophen or aspirin
- (B) Hydrocodone in combination with acetaminophen or ibuprofen (not to exceed a 72-hour supply in accordance with §2 of the Optometric Practice and Licensure Act)
- (C) pentazocine
- (D) propoxyphene
- (E) tramadol

(9) Anti-allergy

(i) Antihistamines and Mast Cell Stabilizers – Topical Only

- (A) alcaftadine
- (B) antazoline
- (C) azelastine

- (D) bepotastine besilate
- (E) cetirizine
- (F) cromolyn
- (G) emedastine difumarate
- (H) epinastine
- (I) ketotifen fumarate
- (J) levocabastine
- (K) lodoxamide
- (L) nedocromil
- (M) olopatadine
- (N) pemirolast potassium
- (O) pheniramine
- (P) pyrilamine

(10) Steroids – Oral and Topical

(i) Steroids - Oral

- (A) methylprednisolone
- (B) prednisone

(ii) Steroids – Topical

- (A) dexamethasone
- (B) difluprednate
- (C) fluorometholone
- (D) hydrocortisone
- (E) loteprednol
- (F) medrysone
- (G) prednisolone
- (H) rimexolone
- (I) triamcinolone

(iii) Antibiotic-Steroid Combination Agents

- (A) dexamethasone-tobramycin
- (B) fluorometholone-sulfacetamide sodium
- (C) gentamicin sulfate-prednisolone acetate
- (D) lotoprednol etabonate-tobramycin

(E) neomycin sulfate-polymixin B sulfate-dexamethasone

(F) prednisolone acetate-sulfacetamide sodium

(11) Immunomodulators – Topical Only

(i) Cyclosporine

(ii) Lifitegrast

(12) Glaucoma Agents – Oral and Topical

(i) Glaucoma – Oral

(A) Carbonic Anhydrase Inhibitors

(I) acetazolamide

(II) methazolamide

(ii) Adrenergic Receptor Agonists - Topical

(A) Non-selective

(I) dipivefrin

(II) epinephrine

(B) Selective Alpha 2 Agonists

(I) apraclonidine

(II) brimonidine

(iii) Beta Adrenergic Receptor Blockers - Topical

(A) Non-selective

(I) carteolol

(II) levobunolol

(III) metipranolol

(IV) timolol

(B) Selective

(I) betaxolol

(II) levobetaxolol

(iv) Cholinergic Receptor Agonists - Topical

(A) Direct Acting

- (I) carbachol
- (II) pilocarpine

(B) Indirect Acting

- (I) demecarium
- (II) echothiophate iodide
- (III) physostigmine

(v) Prostaglandin Analogs - Topical

(A) Docosanoid Derivatives

- (I) unoprostone

(B) Eicosanoid Derivatives

- (I) bimatoprost
- (II) latanoprost
- (III) travoprost
- (IV) latanoprostene bunod

(C) Prostanoid Receptor Agonists

- (I) tafluprost

(vi) Topical Carbonic Anhydrase Inhibitors - Topical

- (A) brinzolamide
- (B) dorzolamide

(vii) Rho kinase Inhibitors - Topical

- (A) netarsudil

(13) Nerve Growth Factor

- (i) cenegermin (Oxervate)

Approval includes combination drugs of the above approved list.